Headquarters: North Chicago, Illinois
2017 prescription sales: $27.7 billion
Projected 2024 sales: $37.2 billion
Since it was spun off from Abbott in 2013, AbbVie has been a one-trick pony, riding to success on the back of Humira, the world’s top-selling drug. And despite the fact that Humira's original patent expired in 2016, it will still continue to hold that ranking in 2024, ensuring the North Chicago, Illinois-based company a spot on the list of top 10 companies by revenue for that year.
Humira will actually be shedding sales by then, with revenues projected by Evaluate at $15.23 billion, down from $18.92 billion in 2017. Still, its sales preeminence is protected until 2024 by the fact it is generally the preferred first-line TNF inhibitor in immunology, the chronic nature of its use and thanks to deals it reached with Amgen and Biogen that delay biosimilar erosion in the U.S. until 2023. The company has secured dozens of additional patents that have made it challenging for biosim competitors to reach the U.S. market.
With its ABBV-599 (a BTK/JAK1 inhibitor) and ABBV-3373 (a TNF inhibitor antibody-cytotoxic drug conjugate) expected to be the long-term successors to Humira, the drugmaker will dominate the lucrative anti-rheumatics market until then.
Outside of that category, AbbVie will get help from cancer fighter Imbruvica, which it shares with Johnson & Johnson and which is projected to place fourth in worldwide oncology sales in 2024 with $9.56 billion. The company purchased its share of the drug in its 2015 Pharmacyclics buyout worth $21 billion.
Add into the equation AbbVie’s Mayret, a pan-genotypic antiviral, that was launched in 2017 at a deep discount and which has been eating up market share. It is forecast to have sales of $2.9 billion in 2024, an amount that will place the company at number three among the top 10 companies for antivirals.